(Submitted for publication June 4, 1959 ; accepted July 17, 1959) Long term administration of aldosterone (1) or desoxycorticosterone acetate (DCA) (2) to normal subjects has been shown, in certain instances, to produce continued renal potassium loss but only transient sodium and chloride retention. This adjustment of the renal response to sodium-retaining adrenal steroids has been termed an "escape" (3) from the expected effects of these compounds, and is seen clinically in the absence of edema with primary aldosteronism. The mechanism of this "escape" from sodium retention, that occurs despite continued excess of steroid sodium-retaining substances, is unknown. Some findings have suggested that the adrenal gland may play a role by producing a substance which either promotes sodium excretion or inhibits the sodium-retaining effect of other hormones.
An adrenal cortical "salt-losing hormone" was postulated by Wilkins and Lewis (4) and Jailer (5) to explain renal salt loss in cases of congenital adrenal hyperplasia. Rosemberg (6) suggested that this might be explained by an aldosterone-inhibiting effect of certain 21-desoxypregnane steroids, and Klein and co-workers (7) reported that partially purified material from urine of patients with congenital adrenal hyperplasia caused increased urinary sodium excretion in rats. Recently, Neher, Meystre and Wettstein (8) reported the isolation of 3a,16a-dihydroxy-pregnan-20-one from patients with the adrenogenital saltlosing syndrome and demonstrated a salt-losing potential of this steroid in adrenalectomized rats. Increased renal sodium excretion has been re-lated to several other steroid compounds as well. Thorn and co-workers (9) reported that patients with Addison's disease who conserved sodium, while receiving 5 mg. of DCA per day, showed an immediate increase in sodium excretion when 100 mg. of cortisone acetate per day was added. Progesterone has been shown by Landau and associates (10, 11) to result in natriuresis in normal subjects and treated patients with Addison's disease, and by Kagawa (12) to block the sodiumretaining effect of DCA in rats. Johnson (13) and Axelrod, Cates, Johnson and Luetscher (14) found that certain 11-oxycorticosteroids and 11-desoxycorticosteroids produced increased sodium excretion in water-loaded, adrenalectomized rats.
A synthetic steroid-17-spirolactone, 3-(3-oxo-17,8-hydroxy-4-androsten-17a-yl)-propionic acid alactone, and its 19-"nor" analog, counteract the sodium-retaining properties of DCA and aldosterone, possibly as a competitive inhibitor (15, 16) . Neher and co-workers (17) have isolated another compound, 33,16a-dihydroxy-allopregnan-20-one, from hog adrenals which, under certain biological conditions, also acts as a sodium-excreting factor.
Additional interest in the role of the adrenal gland in the "escape" was stimulated by the reports of severe edema in some patients with Addison's disease treated solely with DCA (18) (19) (20) (21) (22) (23) , in contrast to the response of normal subjects (1, 2) . Also, in canine studies, Kovach and asso- ciates (24) reported that adrenalectomy prevented an expected increase in sodium excretion following intracarotid injection of hypertonic sodium chloride.
In the light of these observations, the following study of the "escape" mechanism in patients with Addison's disease given large amounts of aldo- provided by Drs. Robert Gaunt and C. H. Sullivan, Ciba Pharmaceutical Products, Inc., Summit, N. J.). The authenticity of this material was tested by paper chromatography before and after enzymatic hydrolysis. Recovery of steroid with the characteristics of aldosterone was consistent with a pure compound with the exception that a small amount of the aldosterone was initially not acetylated. It was administered intramuscularly in sesame oil in divided doses at eight hour intervals. DCA was administered intramuscularly every 12 hours. Vasopressin (Pitressin®) was given to one patient subcutaneously in aqueous suspension every eight hours.
Although endogenous adrenal corticosteroid secretions were not a factor in these studies, cortisone given as maintenance therapy could not be completely eliminated. The studies were designed with variations in cortisone dosage to eliminate its importance to a degree compatible with the health of the subjects. Study III: Cortisone withdrawal during "escape" from DCA ( Figure 3) Another bilaterally adrenalectomized male, age 30, was given 45 mg. of DCA daily for nine days while cortisone was gradually diminished from 37.5 to 10 mg. daily. Sodium intake was 130 mEq. and potassium, 76 mEq. daily. Sodium excretion fell to 49 mEq. on the first day of DCA given in conjunction with 0.2 mg. of 9-a-fluorohydrocortisone, the maintenance level of mineralocorticoid in this case. On the fourth and fifth days of DCA, when only 15 mg. of cortisone was being given, sodium excretion increased to 100 and 137 m'Eq. per day. Thereafter a cyclic pattern of sodium excretion, previously seen during the "escape," continued despite further reduction of the cortisone dosage to 10 mg. per day. It is noteworthy that the "escape" occurred in this case after a weight gain of only 0.7 Kg. as compared to a weight gain of 2.5 to 3.0 Kg., as seen in normal subjects (1) and the other patients in this study. A probable explanation for this finding is that excess body sodium and water were already present when DCA was first given, due to daily use of 0.2 mg. of 9-a-fluorohydrocortisone as maintenance therapy. This explanation is supported by other studies which showed that the sodium-retaining effects of 9-a-fluorohydrocortisone were inversely related to the initial exchangeable sodium in patients with Addison's disease (27 those seen in the normal subjects, it is unlikely that secretion of an adrenal cortical "sodiumexcreting" hormone is responsible for the return to sodium balance which occurs during continued administration of sodium-retaining steroid.
Whether the "escape" phenomenon would occur or continue in all patients with Addison's disease treated solely with aldosterone or DCA cannot be determined from this study. Diminution or withdrawal of glucocorticoid therapy in three of the studies did not indicate that the "escape" depends on cortisone but the period of withdrawal from cortisone was not prolonged. Reports describing treatment of patients with Addison's disease with DCA alone indicate that many gained not more than 2 to 4 Kg. and did not become severely edematous despite administration of up to 40 mg. of DCA daily combined with large sodium chloride intake (28) (29) (30) (31) (32) . However, several cases of massive edema and congestive heart failure have, been attributed to DCA therapy (18) (19) (20) (21) (22) (23) . The number of complicating factors which may have prevailed make the interpretation of these cases difficult. Pre-existing cardiac or renal disease may have been present in some (19, 21, 23) , and others were severely ill due to adrenal insufficiency. In this respect, it should be noted that continued sodium retention is not the normal response to a mineralocorticoid, and that patients with congestive heart failure, cirrhosis with ascites, or nephrosis, respond differently from normal subjects (33) . These patients show virtually complete sodium retention, continuous weight gain without an "escape" and urinary potassium excretion not in excess of intake. Patients with preexisting abnormal sodium retention and edema, or patients with low cardiac or hepatic reserve with a tendency to edema formation, would not be expected to "escape" from the sodium-retaining effects of aldosterone or other mineralocorticoids.
It may be possible that severe, untreated glucocorticoid deficiency would result in abnormal renal function and continued sodium chloride retention during treatment with a mineralocorticoid. This is not to say, however, that an adrenal hormone is directly responsible for the "escape" phenomenon.
SUMMARY
Five patients with Addison's disease, in two due to bilateral adrenalectomy, received large amounts of aldosterone or desoxycorticosterone acetate while on constant diets. Glucocorticoid therapy was varied in the different patients as follows. It was held constant, gradually reduced after the "escape" from sodium retention, gradually reduced before and during the "escape," and completely omitted. In one study, Pitressin® was given with aldosterone. In each of these patients with Addison's disease, sodium chloride retention was transient and apparently was not acutely affected by change in glucocorticoid therapy. It is concluded that an adrenal cortical "sodium-excreting" hormone is not responsible for the "escape" from sodium retention that occurs despite continued administration of sodiumretaining hormone.
